Bachvarov, Dimcho

Professional position: Full Professor, Dept. Molecular Medicine, Fac. Medicine, Laval University

Tel: (418) 525-4444, ext. 15590

Fax: (418) 691-5439

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

 

EDUCATION

 

Institution & location

Degree

Year confered

Supervisor

Field of study

University of Sofia, Bulgaria

Bulg. Acad. Sci., Sofia,  

Bulgaria

Bulg. Acad. Sci., Sofia,

Bulgaria

Univ. New Brunswick,

Fredericton NB, Canada

Laval University, PQ, Canada

B.Sc.

M.Sc.

Ph.D.

Post-doc

Post-doc

1978

1980

1986

1987

1991

Dr. Margarita Stambolova

Dr. George Markov

Dr. Ivan Ivanov

Dr. Ernest Jay

Dr. Tom Moss

biochemistry

molecular biology

molecular biology

molecular biology

molecular biology

 

 

ACADEMIC AND RESEARCH EXPERIENCE

 

Position Institution & Country

Department and Faculty

Start

End

Professor, Laval University

Medicine, Medicine

07/2007 -

 

Associate Professor, Laval University

Medicine, Medicine

07/2005

06/2007

Professeur agrégé subventionnel, Laval University

Medicine, Medicine

07/2002

06/2005

Professeur adjoint subventionnel, Laval University

Medicine, Pharmacology

07/1997

06/2002

Professeur associe, Laval University

Medicine, Pharmacology

08/1994

06/1997

Chercheur associé, CHUQ

Centre de recherche-HDQ

09/1993

07/1994

Professionel de recherche, CHUQ

CHUL – Endomol.

10/1991

08/1993

Research Associate, Bulg. Acad. Sci. Bulgaria

Institute of mol. biology

12/1987

04/1990

Research Assistant, Bulg. Acad. Sci. Bulgaria

Institute of mol. biology

01/1981

03/1983

 

DISTINCTIONS/AWARDS

 

Name/Type

Institution & Country

Start

End

Specialty

Amount

Nominative Scholarship Award (Senior)

FRSQ

CANADA

07/2002

06/2005

cancer biology

$186,000

Scholarship Research award

Centre de recherché-HDQ, CANADA

07/2001

06/2002

cancer biology

$58,000

Nominative Scholarship Award (Junior II)

FRSQ

CANADA

07/1999

06/2001

molecular

biology

$116,699

The Ernest JB Tomlinson

Scholarchip Award

Kidney Foundation of

Canada

07/1997

06/1999

molecular

biology

$90,000

Postdoctoral Fellowship’ Bulg. Ministry of Education

Univ. New Brunswick, CANADA

12/1986

11/1987

molecular

biology

$12,000

FEBS; Short-Term Visit Award for young scientists

Univ. Tübingen, GERMANY

04/1980

06/1980

molecular

biology

$3,000

ACTIVITIES/CONTRIBUTIONS

 

Graduate teaching (2001 - )

Cours aux 2e et 3e cycles; Théorie des récepteurs PHC-62270(2 crédits); Faculté de médecine, Université Laval, Département de Médecine (division de pharmacologie)

 

Academic duties: external evaluator (2003 - )

MSc thesis Alain Labbé, Université Laval, 2011

Membre du jury Jean-Phlippe Brosseau (doctorat), Université Sherbrooke, 2010

MSc thesis, Vincent Ménard, Université Laval, 2010

PhD thesis Stéphane Ouellet, Université Laval 2006

MSc thesis Mahine Ivanga, Université Laval, 2006

PhD thesis Michela Bossolasco, Université de Montréal, 2005

PhD thesis Christiane St-Amant, Université de Sherbrooke, 2005

MSc thesis François Deschênes, Université Laval, 2005

MSc thesis François Vigneault, Université Laval, 2004

MSc thesis Yaned Patricia Gaitan Nieto, Université Laval, 2003

Supervision of graduate students

Name

Type of Training

Years

Supervised

Title of Project or Thesis

Present Position

Mohamed Newman

M.Sc.

2011-

Identification de biomarqueurs prédictifs du traitement antihormonal ciblé de patients avec un cancer ovarien

Zhi Qiang Wang

Ph.D.

2011-

Characterization of novel epigenetic targets in ovarian cancer

Xuan Bich Trinh

Post-doc

2011-

Identification de biomarqueurs prédictifs du traitement antihormonal ciblé de patients avec un cancer ovarien

Jean-Francois Pelletier

M.Sc.

2011

Characterization of novel hypomethylated genes in ovarian cancer

Mamadou Keita

Ph.D.

2009-

Comprehensive screening for novel epigenetic targets in ovarian cancer by functional epigenomics

Pierre-Luc Mercier

M.Sc.

2008-2010

Characterization of novel epigenetic targets in ovarian cancer by DNA methylation profiling

Kether Guerrero

M.Sc.

2008-2010

Characterization of novel epigenetic targets in ovarian cancer by DNA methylation profiling

Sylvain L'Esperance

Ph.D.

2005-2008

Déterminants moléculaires de la chimiorésistance dans les cancers ovariens avances

Scientist, DiagnoCure

Geneviéve Synnott

M.Sc.

2004 -2006

Mode d’action antiprolifératif des Nutlins dans les cellules tumorales

Biology teacher in the Ste-Foy college, Que.

Ion Popa

(co-director)

M.Sc.

2002 -2004

Validation de facteurs potentials de chimiorésistance du cancer de l’ovaire par immunohistochimie

MD resident (pathology),

HDQ hospital

Stéphanie Jutras

M.Sc.

2001 -2003

Potentiel thérapeutique des

antagonistes des récepteurs des kinines

Research associate in a

pharmaceutical company

Geneviève St-Gelais

M.Sc.

2001 -2003

Caractérisation fonctionnelle initiale du gène Hermasky-Pudlak syndrome-3 (HPS3)

Research associate in a

pharmaceutical company

Rainelli

Koumangoye

M.Sc.

2000 -2002

Implication de certains composants du système kallikréine-kinine (SKK) dans la pathophysiologie rénale

Ph.D. student

Univ. Miami,

USA

Isabelle Maltais

M.Sc.

1999 -2001

Études des polymorphisms dans les genes des récepteurs de kinines

Supervisor Scientist, Federal Agency for Food

Control, Ste-Hyacinthe, Que.

 

 

Supervision of undergraduate students

Luc Bastien, 05-08/2001, Nicolas St-Sauveur, 05-08/2002, Stéphane Turcotte 05-12/2005, Pierre-Luc Mercier, 05-08/2007, Kether Guerrero, 05-08/2007, Emanuelle Buteau 05-08/2009; Jean-François Pelletier 04-08/2010

 

Appointments, Committees and Memberships (2001 - )

Co-president of the local organizing Committee – VIth Canadian Conference on Ovarian Cancer Research, May 27-29th, Quebec City, Canada

Head of the FRSQ-réseau cancer Core Genomic Facility in Quebec city (see: http://www.crhdq.ulaval.ca/client/en/services/dna.html)

Responsible – Ovarian Tumor and Clinical Data Bank (see: http://www.rrcancer.ca)

FRSQ; Member of the Committee for Postdoctoral Scholarships (volet clinique) 2009-2011

FRSQ; Member of the Committee for Scholarships (chercheurs-boursiers et chercheurs-boursiers cliniciens Junior 1) 2006-2008

World Journal of Clinical Oncology: Member of the Editorial Board (http://www.wjgnet.com/2218-4333/edboard_22.htm )

Cancer Reserch Society; Member of Panel C Grant Evaluation Committee (Gènes suppresseurs de tumeur, oncogènes et réparation de l'ADN) 2000-2002

Cancer Reserch Society; Member of Panel C Grant Evaluation Committee (Gènes suppresseurs de tumeur, oncogènes et réparation de l'ADN) 2006-2008

Department of Defense, U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs (CDMRP), Member of Panel 1 Grant Evaluation Committee (Ovarian Cancer Research Program) 2009

External evaluator: Canadian Institutes of Health Research, FRSQ, Heart & Stroke Foundation of Canada, The Crohn and Colitis Foundation of Canada, Le Fonds de la recherche sur la nature et les technologies (FRNT), The Wellcome Trust (Great Britain)

Member of the FRSQ-supported Cancer Research Network (FRSQ-réseau cancer) in the province of Québec

Co-president of the Research Committee, FRSQ-réseau cancer, breast and ovarian cancer axis

Member of the Executive Committee, FRSQ réseau-cancer, breast and ovarian cancer axis

Member of the Canadian Tumor Repository Network

Member of the Canadian Cancer Etiology research Network

Organisation of the 2e Journée scientifique– FRSQ réseau-cancer, axe banque de tissus et de données, Centre de recherche de l’Hôtel-Dieu de Québec 05/2003

 

Evaluation of scientific articles (extermal reviewer)

Hypertension, Journal of the American Society of Nephrology, Circulation Research, Regulatory Peptides, Canadian journal of Physiology and Pharmacology, Cardiovasvcular Research, Journal of Clinical Investigation, Gynecological Oncology, Gene Therapy, Clinical Medicine, Tumori

 

Invited presentations

2011     Batchvarov D. Keita M., Selvamohan R., Batchvarova M., Paquet E. Analyse globale des altérations aberrantes de la méthylation de l'ADN dans le cancer de l'ovaire. La 53è réunion annuelle du Club de Recherche Clinique du Québec (CRCQ) à l’hôtel Mont Gabriel du 22 au 24 septembre 2011.

2010   Bachvarov, D. DNA methylation alterations in ovarian cancer: impact on cancer initiation, progression and response to therapy. Séminaire inter-laboratoire. CHUQ, Centre de recherché en cancérologie, Hôtel-Dieu de Québec, 20 octobre 2010.

2010      Première rencontre interaxe du FRSQ-Réseau de Recherche en Cancer; 17-19 juin 2010, Orford (Québec) Canada. Characterization of novel aberrantly methylated genes with potential functional role in ovarian tumorigenesis”.

2010      Regards croisés Québec - Flandre partenaires en recherche et innovation. May 19-20, 2010, Brussels, Belgium “Genomic and epigenomic approaches in translational cancer research: focus on ovarian cancer etiology and therapy”.

2009  3rd Sino-Canada Bilateral Workshop in Reproductive Health Research. November 26-29,2009, Nanjing, China “Identification of molecular mechanisms and biomarkers involved in ovarian cancer initiation, progression and response to chemotherapy: towards novel treatment strategies”.

2009  Bulgarian Japanese Symposium “Genomics and Proteomics of Personalized medicine. March 19-20, Sofia, Bulgaria “Molecular mechanisms of ovarian cancer chemoresistance

2009 1st Quebec Conference on Therapeutic Resistance in Cancer. March 27-28, Montreal PQ, Canada. “Molecular determinants of ovarian cancer chemoresistance

2009 The 2nd World Cancer Congress, June 22-25, Beijing, China. “Molecular determinants of ovarian cancer chemoresistance”. Chair of session: “Gynecological Cancers: Breast Cancer vs Ovarian Cancer - Part 2”.

2008     Conférencier invite par Dr. Éric Asselin, Université de Québec a Trois-Rivières“ Determinants of ovarian cancer chemoresistance: Identification of novel chemoresistance markers by gene expression profiling” 

2008     16e réunion annuelle des biologistes de la reproduction, March 9-11, 2008, Forêt Montmorency, Université Laval “Molecular determinants of ovarian cancer chemoresistance” 

2007   The 12th World Congress on Advances in Oncology; 11-13 October, Crete, Greece “Molecular mechanisms of ovarian cancer chemoresistance”

2007       25th Annual Ottawa reproductive Workshop, May 2, 2007, Ottawa.

             “Genomics-Based Strategies in Studying Ovarian Cancer Chemoresistance”

2006       US-Canadian Academy of Pathology Annual Congress, Atlanta GA, February 11-17 “Validation of some potential chemoresistance factors in ovarian cancer by IHC”

2006   The 3rd National Conference on Ovarian Cancer Research; 13–16 May, Vancouver, BC

               “Gene expression patterns of chemoresistant and chemosensitive ovarian serous adenocarcinomas with possible prognostic value in response to initial chemotherapy

2006   The 3rd National Conference on Ovarian Cancer Research; 13–16 May, Vancouver, BC. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors

  1. 20051st international conference “Exploring the Future of Local Vascular and Inflammatory Mediators” Lund, Sweden, May 26-28

             “Gene expression profiling using bradykinin B1 and B2 receptor knockout mice identifies roles of both receptors in renal physiology and pathology”

2005     Conférencier invite par Dr. Jean-Loup Bascands, INSEM, Toulouse, France.

             “New approaches in ovarian cancer management”

2005     Symposium on Ovarian Cancer: Prevention & Detection of the Disease & its Recurrence. Pittsburgh, Pennsylvania October 24 & 25

Gene expression profiling of ovarian tumours obtained prior to and after chemotherapy: identification of putative markers implicated in mechanisms of chemoresistance

2005     Oncology seminars: « Les mercredis d’oncologie » CHUQ, Hôpital Hôtel-Dieu de Québec. November 30th. “New approaches in ovarian cancer management

2004     Second Canadian Conference on Ovarian Cancer Research, May 16-18, Ottawa, Ontario “Identification of markers with prognostic significance in ovarian cancer chemotherapy”

2004       Journée de la recherche de la Faculté de médecine, Université Laval, 3 juin                          

     “ Identification des marqueurs ayant on pronostique significatif pour la chimiothérapie du cancer ovarien

2004       La Journée de la Statistique, présente par le Comité pour l’Avancement de la Statistique de l’Université Laval (C.A.S.U.L), Québec, 13 février

Methods for analysis of differential gene & protein expression and their clinical applications”

RECENT PUBLICATIONS (last 5 years)

 

Angers M, Drouin R, Bachvarova M, Paradis I, Hiromura M, Usheva A, Bachvarov D. In vivo DNase I-mediated footprinting analysis along the human bradykinin B1 receptor (BDKRB1) gene promoter: evidence for cell-specific regulation. Biochem J. 2005; 389(1):37-46.

 

Bachvarov D*, Bachvarova M, Koumangaye R, Klein J, Pesquero JB, Neau E, Bader M, Schanstra JP, Bascands JL. Renal gene expression profiling using kinin B1 and B2 receptor knockout mice reveals comparable modulation of functionally related genes Biol Chem. 2006; 387:15-22.

 

Zimon A, Bissell B, Erat A, von Wald T, Choi C, Reindollar R, Bachvarov D, Usheva A. Genes invoked in the ovarian transition to menopause. Nucl Acids Res. 2006;34(11):3279-3287.

 

L’Esperance, S., Popa, I., Bachvarova, M., Plante, M. Patten, N., Wu, L., Têtu, B. and Bachvarov, D. Gene expression profiling of paired tumor samples obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006; 29(1):5-24.

 

Bachvarov D*, L’Esperance L, Popa I, Bachvarova M, Plante M, Têtu B. Gene expression patterns of chemoresistant and chemosensitive ovarian serous adenocarcinomas with possible prognostic value in response to initial chemotherapy. Int J Oncol. 2006;29(4):919-933.

 

Schanstra J, Bachvarova M, Neau E, Bascands JL, Bachvarov D. Gene expression profiling in the remnant kidney model of wild type and kinin B1 and B2 receptor knockout mice. Kidney Int. 2007;72(4):442-454.

 

L’Esperance, S., Bachvarova, Têtu, B. Mes-Masson, Bachvarov D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics. 2008;9(1):99.

 

Tetu B, Popa I, Bairati I, L’Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D. Immunohistochemical analysis of possible chemoresistant markers identified by micro-arrays on serous ovarian carcinomas. Modern Pathol. 2008;21:1002–10.

 

Guay D, Evoy A-A, Paquet E, Garand C, Bachvarova M, Bachvarov D, and Lebel M. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Cell Biol. 2008;40(11):2492-507.

 

Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barres V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson A-M. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer 2008, 8:346.

 

Bascands JL, Bachvarova M, Neau E, Schanstra J, Bachvarov D. Molecular determinants of LPS-induced acute renal inflammation: implication of the kinin B1 receptor. Biochem Biophys Res Commun. 2009 386(2):407-12.

 

Cusimano A, Antonina Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D’Alessandro N, Montalto G, Melchiorre Cervello M. Novel combination of celecoxib and protyeasome inhibitor MG132 in human hepatocellular carcinoma provides a synergistic anti-tumor effects. Cell Cycle. 2010 Apr 19;9 (7).

 

Jutras S, Bachvarova M, Keita M, Bascands J-L, Mes-Masson A-M, Stewart J, Bachvarov D. Strong cytotoxic effect of the bradykinin antagonist BKM570 in ovarian cancer cells: analysis of the molecular mechanisms of its anti-proliferative action. FEBS J. 2010;277(24):5146-5160

 

Cusimano A, Antonina Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D’Alessandro N, Montalto G, Melchiorre Cervello M. Novel combination of celecoxib and protyeasome inhibitor MG132 in human hepatocellular carcinoma provides a synergistic anti-tumor effects. Cell Cycle. 2010;9(7):1399-410.

 

Cervello Ma, Bachvarov Da, Cusimano A, Sardina F, Azzolina A, Lampiasi N, Giannitrapani L, McCubrey JA, and Giuseppe Montalto G. COX-2-dependent and COX-2-independent mode of action of Celecoxib in human liver cancer cells. OMICS. 2011 Mar 16. [Epub ahead of print]. (aM. Cervello and D. Bachvarov contributed equally to this work.)

 

Chen S, Bellew C, Yao X, Stefkova J, Dipp S, Saifudeen Z, Bachvarov D, El-Dahr SS. HDAC activity is critical for embryonic kidney gene expression, growth and differentiation. J Biol Chem. 2011 Sep 16;286(37):32775-89.

 

Mercier P-L, Bachvarova M, Plante M, Gregoire J, Ghani K, Têtu B, Bairati I, Bachvarov D. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011;5:438-453.

 

Ttrinh XB, Tjalma WAA, Dirix L, Vermeulen PB, Peeters D, Bachvarov D, Plante M, Berns E, Helleman J, Van Laere SJ, Van Dam PA. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One. 2011;6(7):e22469.

 

*I am both the principal investigator and the corresponding author in these papers.

 

 

 

FINANCIAL SUPPORT

A. Currently held or applied for:

Applicant

& co-applicants

Organisation, Type of support, Title of project and Name of applicant (if different)

Amount

per year

Held or

Applied

Period yy - yy

Bachvarov D (PI),

Plante M (co-PI)

CIHR – Dissemination Events

“Sixth Canadian Conference on Ovarian Cancer Research (CCOCR 2012)”

18,500

H

11-12

Bachvarov, D.

Cancer Research Society (CRS), Operating Grant

“Characterization of the hypomethylation status of the RUNX1 and RUNX2 genes in advanced ovarian cancer: possible role of RUNX1 and RUNX2 in ovarian cancer progression, invasion/metastasis and chemoresistance”

60,000

H

11-13

Bachvarov D (PI),

Têtu B, Plante M, Gregoire J, Bairati I.

 

Ministère du Développement Économique, Innovation et Exportation (MDEIE) – Québec; programme PSR-SIIRI (operating)

“Identification de biomarqueurs prédictifs du traitement antihormonal ciblé de patients avec un cancer ovarien”

50,000

 

H

 

11-14

 

Mes-Masson A-M (PI), Provencher D. (co-PI), Huntsman D. (co-PI), Bachvarov D, and 19 other scientists as lead scientific investigators

Terry-Fox Research Institute; Research Initiative (operating

“A Trans-Canadian platform for the development of biomarker driven subtype specific management of ovarian carcinoma”

996,000

H

10-15

Batist, G (PI), Bachvarov D, Chabot B, Basik M, Simard M, Guillemette, C.

Masson J-Y.

FRSQ-Pfizer, group grant (operating)

"Identification and validation of biomarkers of therapeutic resistance in metastatic colorectal cancer”

500,000

H

09-12

Bachvarov, D. (PI)

Têtu, B.

Guillemette, C.

Bairati, I.,Juge, N

NSERC/CIHR, Collaborative Health Research Projects

"Comprehensive screening for novel epigenetic targets in ovarian cancer by functional epigenomics"

123,000

H

08-11

Bachvarov, D.

Fonds de la Recherche en Santé du Québec (FRSQ); operational support;

"Ovarian cancer tissue and primary cell culture banking activities”

70,000

H

11-15

Têtu, B (PI) Bachvarov, D.

Plante, M. Bairati, I. Grégoire, J.

Cancer Research Society (CRS), Operating Grant

"Assessment of novel markers with potential prognostic significance in ovarian cancer"

60,000

H

10-12

 

B. Financial support during the last five years

Applicant

& co-applicants

Organisation, Type of support, Title of project and Name of applicant (if different)

Amount

per year

Period yy - yy

Bachvarov, D

Fonds de la Recherche en Santé du Québec (FRSQ); operational support;

"Ovarian cancer tissue and primary cell culture banking activities”

70,000

 

07-11

 

Bachvarov, D. (PI)

Têtu, B. Plante, M. D’Ouville P.

 

Ovarian Cancer Canada, Operating Grant

“MicroRNA expression profiling in serums of serous ovarian cancer patients: in search for novel blood-based markers for early ovarian cancer detection”

30,000

 

09-10

 

Bachvarov, D. (PI) Têtu, B.

Guillemette, C.

Cancer Research Society (CRS), Operating Grant

"Identification of novel epigenetic targets in ovarian cancer by functional epigenomics"

60,000

 

07-09

 

Têtu, B. (PI), Bairati, I. Bachvarov, D.

Plante, M.,

Bazinet, L.

CRS, Operating Grant

"Green tea intake for maintenance of complete remission in women with advanced ovarian cancer"

60,000

07-09

Bachvarov, D.

Bascands, J-L.

FRSQ/INSERM: International exchange program: Role of kinin receptors in renal pathology

5,000

05-07

Bachvarov, D.

Tetu, B. Poirier, G

CRS Strategic Grants: Genomics and Proteomics of Metastasic Cancer; Operating Grant

“Molecular mechanisms of chemoresistance in advanced ovarian cancer: a pharmacogenomics approach”

150,000

03-06

Chartrand, P.

Bachvarov, D. + 9 other co-applicants

Valorisation Recherche Quebec: Operating Grant

« Platformes structurantes du réseau cancer du FRSQ: modélisations, services d`analyses et banques de tissus et de doneés »

417,730

02-06

Retour en haut

Hôpital Hotel-Dieu de Québec

logo ulavallogochuq